pharma news today obesity glp-1 Overview of GLP-1s GLP-1s and the Unintended Consequences

The substantial barriers to access to GLP-1s reflect existing inequities and poor alignment of incentives in our healthcare system, says study coauthor Katherine Hempstead, senior policy officer at the Robert Wood Johnson Foundation

Subscription traps Perhaps the most frequently reported issue involves unauthorized recurring charges

Can we get similar metabolic/weight-health outcomes without jumping straight to medication? Thats where the whole-food supplement philosophy of Standard Process comes into play

Van Wyk, J

Preclinical studies demonstrate that DSIP can alter pain threshold responses, with observed effects that are not reversed by opioid receptor antagonists such as naloxone, suggesting involvement of non-opioid or indirect neuromodulatory pathways [7]